Drug Approval | December 20, 2022
Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers
Positive opinions based on significant survival benefit
Positive opinions based on significant survival benefit
The investment will enable the company to enter European markets as well as enhance margins in current markets
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
More women centric initiatives being the need of the hour for holistic development
Proceeds from the transaction will be reinvested towards the growth, innovation and expansion of Healthium’s advanced surgery, orthopaedics, wound care and post-surgical care portfolio
GMP-compliant documentation of all manufacturing steps for cell and gene therapies
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
This product is based on Osmotic Controlled Release Oral Delivery System technology
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
Subscribe To Our Newsletter & Stay Updated
